ReLIA Bioengineering

Executive Summary

ReLIA Bioengineering, founded in 2001 and headquartered in Shenzhen, China, is a private diagnostics company specializing in point-of-care testing (POCT) for infectious diseases and immunology. The company leverages chemiluminescence and fluorescent platforms to develop rapid diagnostic equipment and test kits, covering applications such as infectious disease detection, blood typing, and veterinary testing. With a workforce of 200-500 employees and a commercial-stage presence, ReLIA is well-positioned in China's growing POCT market, which is driven by demand for decentralized testing and early disease diagnosis. The company's focus on low-cost, rapid diagnostics aligns with healthcare trends in both human and animal health, offering potential for expansion into broader markets. However, as a private entity with limited public disclosures, financial performance and pipeline details remain opaque, warranting a moderate conviction rating.

Upcoming Catalysts (preview)

• Q3 2026Launch of Multi-Panel Respiratory Pathogen Test Kit70% success
• Q4 2026Strategic Partnership with Global Diagnostic Distributor50% success
• Q1 2027FDA or CE Mark Approval for Select Product40% success